Advances in immunotherapy for melanoma management

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 10, 2016, Pages 2501-2511

  Dany, Mohammed ^a,b   Nganga, Rose ^b   Chidiac, Alissar ^b   Hanna, Edith ^b   Matar, Sara ^b   Elston, Dirk ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

checkpoint inhibitors; immunotherapy; melanoma; tumor immunology

Indexed keywords

BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TALIMOGENE LAHERPAREPVEC; VEMURAFENIB; CANCER VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL DEATH; CELL MIGRATION; CLINICAL TRIAL (TOPIC); COLITIS; DIARRHEA; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; GIANT CELL ARTERITIS; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; MELANOMA; METASTATIC MELANOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROTEIN EXPRESSION; PRURITUS; REVIEW; T LYMPHOCYTE ACTIVATION; THYROIDITIS; UPREGULATION; VITILIGO; ADOPTIVE TRANSFER; PROCEDURES;

ADOPTIVE TRANSFER; ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 84992051053     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1190889     Document Type: Review

References (92)

1. A.Vennepureddy, N.Thumallapally, V.M.Nehru, J.Atallah, T.Terjanian. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res 2016; 8:63
2. A.J.Miller, M.C.MihmJr. Melanoma. N Engl J Med 2006; 355:51-65
3. J.B.Macdonald, A.C.Dueck, R.J.Gray, N.Wasif, D.L.Swanson, A.Sekulic, B.A.Pockaj. Malignant melanoma in the elderly:Different regional disease and poorer prognosis. J Cancer 2011; 2:538-43; PMID:22084644
4. E.Shtivelman, M.Q.Davies, P.Hwu, J.Yang, M.Lotem, M.Oren, K.T.Flaherty, D.E.Fisher. Pathways and therapeutic targets in melanoma. Oncotarget 2014; 5:1701-52; PMID:24743024
5. N.M.La‐Beck, G.W.Jean, C.Huynh, S.K.Alzghari, D.B.Lowe. Immune checkpoint inhibitors:New insights and current place in cancer therapy. Pharmacotherapy 2015; 35:963-76
6. R.A.Willemsen, C.Ronteltap, P.Chames, R.Debets, R.L.Bolhuis. T cell retargeting with MHC class I-restricted antibodies:The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005; 174:7853-8; PMID:15944290
7. J.M.Taube, R.A.Anders, G.D.Young, H.Xu, R.Sharma, T.L.McMiller, S.Chen, A.P.Klein, D.M.Pardoll, S.L.Topalian, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
8. M.Atefi, E.Avramis, A.Lassen, D.J.Wong, L.Robert, D.Foulad, M.Cerniglia, B.Titz, T.Chodon, T.G.Graeber, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20:3446-57; PMID:24812408; http://dx.doi.org/10.1158/1078-0432.CCR-13-2797
9. P.S.Linsley, J.Bradshaw, J.Greene, R.Peach, K.L.Bennett, R.S.Mittler. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996; 4:535-43
10. G.J.Freeman, A.J.Long, Y.Iwai, K.Bourque, T.Chernova, H.Nishimura, L.J.Fitz, N.Malenkovich, T.Okazaki, M.C.Byrne, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443
11. E.Buchbinder, F.S.Hodi. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015; 125:3377-83; PMID:26325034; http://dx.doi.org/10.1172/JCI80012
12. R.D.Harvey. Immunologic and clinical effects of targeting PD‐1 in lung cancer. Clinical Pharmacology & Therapeutics 2014; 96:214-23
13. J.Delyon, M.Maio, C.Lebbe. The ipilimumab lesson in melanoma:Achieving long-term survival. Semin Oncol 2015; 42:387-401; PMID:25965357; http://dx.doi.org/10.1053/j.seminoncol.2015.02.005
14. L.H.Camacho. CTLA-4 blockade with ipilimumab:Biology, safety, efficacy, and future considerations. Cancer Med 2015; 4:661-72; PMID:25619164; http://dx.doi.org/10.1002/cam4.371
15. J.Delyon, M.Maio, C.Lebbe. The ipilimumab lesson in melanoma:Achieving long-term survival. Semin Oncol 2015; 42:387-401; PMID:25965357
16. M.L.Alegre, K.A.Frauwirth, C.B.Thompson. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1:220-8; PMID:11905831; http://dx.doi.org/10.1038/35105024
17. O.Michielin, C.Hoeller. Gaining momentum:New options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev 2015; 41:660-70; PMID:26096079; http://dx.doi.org/10.1016/j.ctrv.2015.05.012
18. V.A.Trinh, B.Hagen. Ipilimumab for advanced melanoma:A pharmacologic perspective. J Oncol Pharm Pract 2013; 19:195-201; PMID:23047236; http://dx.doi.org/10.1177/1078155212459100
19. Z.Hanaizi, B.van Zwieten-Boot, G.Calvo, A.S.Lopez, M.van Dartel, J.Camarero, E.Abadie, F.Pignatti. The european medicines agency review of ipilimumab (yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy:Summary of the scientific assessment of the committee for medicinal products for human use. Eur J Cancer 2012; 48:237-42
20. C.M.Balch, J.E.Gershenwald, S.J.Soong, J.F.Thompson, M.B.Atkins, D.R.Byrd, A.C.Buzaid, A.J.Cochran, D.G.Coit, S.Ding, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
21. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
22. F.S.Hodi, D.Lawrence, C.Lezcano, X.Wu, J.Zhou, T.Sasada, W.Zeng, A.Giobbie-Hurder, M.B.Atkins, N.Ibrahim, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2:632-42; PMID:24838938; http://dx.doi.org/10.1158/2326-6066.CIR-14-0053
23. S.M.Ansell, S.A.Hurvitz, P.A.Koenig, B.R.LaPlant, B.F.Kabat, D.Fernando, T.M.Habermann, D.J.Inwards, M.Verma, R.Yamada, et al. Phase I study of ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-hodgkin lymphoma. Clin Cancer Res 2009; 15:6446-53; PMID:19808874; http://dx.doi.org/10.1158/1078-0432.CCR-09-1339
24. A.Ribas. Anti-CTLA4 antibody clinical trials in melanoma. Update Cancer Ther 2007; 2:133-9; PMID:19543441; http://dx.doi.org/10.1016/j.uct.2007.09.001
25. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, J.Weber, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
26. D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
27. A.M.Eggermont, M.Maio, C.Robert. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol 2015; 42:429-35; PMID:25965361
28. J.S.Weber, R.Dummer, V.de Pril, C.Lebbe, F.S.Hodi. MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab:Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-82; PMID:23400564; http://dx.doi.org/10.1002/cncr.27969
29. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23
30. A.V.Maker, J.C.Yang, R.M.Sherry, S.L.Topalian, U.S.Kammula, R.E.Royal, M.Hughes, M.J.Yellin, L.R.Haworth, C.Levy, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29:455-63; PMID:16799341; http://dx.doi.org/10.1097/01.cji.0000208259.73167.58
31. J.S.Weber, K.C.Kahler, A.Hauschild. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
32. J.D.Wolchok, A.Hoos, S.O'Day, J.S.Weber, O.Hamid, C.Lebbe, M.Maio, M.Binder, O.Bohnsack, G.Nichol, et al. Guidelines for the evaluation of immune therapy activity in solid tumors:Immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
33. S.J.Antonia, J.Larkin, P.A.Ascierto. Immuno-oncology combinations:A review of clinical experience and future prospects. Clin Cancer Res 2014; 20:6258-68; PMID:25341541; http://dx.doi.org/10.1158/1078-0432.CCR-14-1457
34. A.V.Maker, G.Q.Phan, P.Attia, J.C.Yang, R.M.Sherry, S.L.Topalian, U.S.Kammula, R.E.Royal, L.R.Haworth, C.Levy, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2:A phase I/II study. Ann Surg Oncol 2005; 12:1005-16; PMID:16283570; http://dx.doi.org/10.1245/ASO.2005.03.536
35. J.E.Ohm, D.P.Carbone. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001; 23:263-72; PMID:11444391
36. A.Boni, A.P.Cogdill, P.Dang, D.Udayakumar, C.N.Njauw, C.M.Sloss, C.R.Ferrone, K.T.Flaherty, D.P.Lawrence, D.E.Fisher, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9; PMID:20551059; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118
37. A.Ribas, F.S.Hodi, M.Callahan, C.Konto, J.Wolchok. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc1302338
38. Y.Agata, A.Kawasaki, H.Nishimura, Y.Ishida, T.Tsubata, H.Yagita, T.Honjo. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765-72; PMID:8671665
39. Y.Ishida, Y.Agata, K.Shibahara, T.Honjo. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-95; PMID:1396582
40. H.Dong, S.E.Strome, D.R.Salomao, H.Tamura, F.Hirano, D.B.Flies, P.C.Roche, J.Lu, G.Zhu, K.Tamada. Tumor-associated B7-H1 promotes T-cell apoptosis:A potential mechanism of immune evasion. Nat Med 2002; 8:793-800
41. Y.Iwai, M.Ishida, Y.Tanaka, T.Okazaki, T.Honjo, N.Minato. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7; PMID:12218188; http://dx.doi.org/10.1073/pnas.192461099
42. L.Khoja, M.O.Butler, S.P.Kang, S.Ebbinghaus, A.M.Joshua. Pembrolizumab. J Immunother Cancer 2015; 3:1-13
43. S.L.Topalian, M.Sznol, D.F.McDermott, H.M.Kluger, R.D.Carvajal, W.H.Sharfman, J.R.Brahmer, D.P.Lawrence, M.B.Atkins, J.D.Powderly, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
44. J.R.Brahmer, C.G.Drake, I.Wollner, J.D.Powderly, J.Picus, W.H.Sharfman, E.Stankevich, A.Pons, T.M.Salay, T.L.McMiller, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
45. C.Robert, G.V.Long, B.Brady, C.Dutriaux, M.Maio, L.Mortier, J.C.Hassel, P.Rutkowski, C.McNeil, E.Kalinka-Warzocha. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30
46. A.A.Tarhini. Immunotherapy of melanoma. Curr Mol Pharmacol 2015; PMID:26177647.
47. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54
48. E.Cha, J.Wallin, M.Kowanetz. PD-L1 inhibition with MPDL3280A for solid tumors. 2015; 42:484-7
49. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med 2013; 369:134-44
50. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26):2521-32; http://dx.doi.org/10.1056/NEJMoa1503093; Epub 2015 Apr 19
51. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
52. R.S.Herbst, J.Soria, M.Kowanetz, G.D.Fine, O.Hamid, M.S.Gordon, J.A.Sosman, D.F.McDermott, J.D.Powderly, S.N.Gettinger. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7
53. J.S.Weber, S.P.D'Angelo, D.Minor, F.S.Hodi, R.Gutzmer, B.Neyns, C.Hoeller, N.I.Khushalani, W.H.Miller, C.D.Lao. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology 2015; 16:375-84
54. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.Gordon, K.Reed. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33
55. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34
56. K.Kim, A.D.Skora, Z.Li, Q.Liu, A.J.Tam, R.L.Blosser, L.A.DiazJr, N.Papadopoulos, K.W.Kinzler, B.Vogelstein, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014; 111:11774-9; PMID:25071169; http://dx.doi.org/10.1073/pnas.1410626111
57. Z.A.Cooper, V.R.Juneja, P.T.Sage, D.T.Frederick, A.Piris, D.Mitra, J.A.Lo, F.S.Hodi, G.J.Freeman, M.W.Bosenberg, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014; 2:643-54; PMID:24903021; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215
58. K.M.Mahoney, P.D.Rennert, G.J.Freeman. Combination cancer immunotherapy and new immunomodulatory targets. Nature reviews Drug discovery 2015; 14:561-84
59. W.R.Godfrey, F.F.Fagnoni, M.A.Harara, D.Buck, E.G.Engleman. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 1994; 180:757-62; PMID:7913952
60. A.D.Weinberg, K.W.Wegmann, C.Funatake, R.H.Whitham. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162:1818-26; PMID:9973447
61. I.Gramaglia, A.D.Weinberg, M.Lemon, M.Croft. Ox-40 ligand:A potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161:6510-7; PMID:9862675
62. I.Melero, A.M.Grimaldi, J.L.Perez-Gracia, P.A.Ascierto. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214
63. I.Melero, S.Hervas-Stubbs, M.Glennie, D.M.Pardoll, L.Chen. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106
64. A.Imura, T.Hori, K.Imada, T.Ishikawa, Y.Tanaka, M.Maeda, S.Imamura, T.Uchiyama. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996; 183:2185-95; PMID:8642328
65. M.R.Alderson, C.A.Smith, T.W.Tough, T.Davis‐Smith, R.J.Armitage, B.Falk, E.Roux, E.Baker, G.R.Sutherland, W.S.Din. Moslecular and biological characterization of human 4‐1BB and its ligands. Eur J Immunol 1994; 24:2219-27
66. A.T.Cheuk, G.J.Mufti, B.Guinn. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004; 11:215-26
67. S.Li, Y.Liu. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clinical pharmacology:advances and applications 2013; 5:47
68. M.Orloff, M.E.Valsecchi, T.Sato. Successes and setbacks of early investigational drugs for melanoma. Expert Opin Investig Drugs 2015; 24:993-7
69. M.Sznol, F.Hodi, K.Margolin, D.McDermott, M.Ernstoff, J.Kirkwood, C.Wojtaszek, D.Feltquate, T.Logan. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). 2008; 26:3007
70. M.F.Sanmamed, I.Rodriguez, K.A.Schalper, C.Onate, A.Azpilikueta, M.E.Rodriguez-Ruiz, A.Morales-Kastresana, S.Labiano, J.L.Perez-Gracia, S.Martin-Algarra, et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rgammanull immunodeficient mice. Cancer Res 2015; 75:3466-78; PMID:26113085; http://dx.doi.org/10.1158/0008-5472.CAN-14-3510
71. A.Makkouk, C.Chester, H.E.Kohrt. Rationale for anti-CD137 cancer immunotherapy. Eur J Cancer 2016; 54:112-9
72. D.J.Schwartzentruber, D.H.Lawson, J.M.Richards, R.M.Conry, D.M.Miller, J.Treisman, F.Gailani, L.Riley, K.Conlon, B.Pockaj. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27
73. J.Ozao-Choy, D.J.Lee, M.B.Faries. Melanoma vaccines:Mixed past, promising future. Surg Clin North Am 2014; 94:1017-30
74. F.Belli, A.Testori, L.Rivoltini, M.Maio, G.Andreola, M.R.Sertoli, G.Gallino, A.Piris, A.Cattelan, I.Lazzari, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:Clinical and immunologic findings. J Clin Oncol 2002; 20:4169-80; PMID:12377960
75. E.C.Hsueh, D.L.Morton. Antigen-based immunotherapy of melanoma:Canvaxin therapeutic polyvalent cancer vaccine. 2003; 13:401-7
76. O.Klein, C.Schmidt, A.Knights, I.D.Davis, W.Chen, J.Cebon. Melanoma vaccines:Developments over the past 10 years. 2011
77. A.M.Eggermont, S.Suciu, P.Rutkowski, J.Marsden, M.Santinami, P.Corrie, S.Aamdal, P.A.Ascierto, P.M.Patel, W.H.Kruit, et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor >1.5 mm in patients with stage II melanoma:Results of the EORTC 18961 randomized phase III trial. J Clin Oncol 2013; 31:3831-7; PMID:24019551; http://dx.doi.org/10.1200/JCO.2012.47.9303
78. Y.Kawakami, P.F.Robbins, R.F.Wang, M.Parkhurst, X.Kang, S.A.Rosenberg. The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 1998; 21:237-46
79. H.M.Zarour, J.M.Kirkwood. Melanoma vaccines:Early progress and future promises. 2003; 22:68-75
80. F.O.Nesrua, S.Atuaolcl, M.GILLIEM, Y.SUNZY, S.Gimasr. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Peptides 1:A2
81. W.J.Lesterhuis, G.Schreibelt, N.M.Scharenborg, H.M.H.Brouwer, M.P.Gerritsen, S.Croockewit, P.G.Coulie, R.Torensma, G.J.Adema, C.G.Figdor. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 2011; 60:249-60
82. J.M.Greene, E.J.Schneble, D.O.Jackson, D.F.Hale, T.J.Vreeland, M.Flores, J.Martin, G.S.Herbert, M.O.Hardin, X.Yu. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunol Immunother 2016; 65:383-92
83. R.H.I.Andtbacka, F.A.Collichio, T.Amatruda, N.N.Senzer, J.Chesney, K.A.Delman, L.E.Spitler, I.Puzanov, S.Doleman, Y.Ye. OPTiM:A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. 2013; 31:LBA9008
84. I.Puzanov, M.M.Milhem, R.H.I.Andtbacka, D.R.Minor, O.Hamid, A.Li, M.Chastain, K.Gorski, A.Anderson, A.M.Vanderwalde. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. 2014; 32:9029
85. R.A.Jabulowsky, C.Loquai, M.Diken, L.M.Kranz, H.Haas, S.Attig, C.M.Britten, J.Buck, E.Derhovanessian, J.Diekmann. Abstract B041:A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma. Cancer Immunol Res 2016; 4:B041
86. L.H.Butterfield. Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 2016; 1-8
87. C.H.June. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446
88. R.Wu, M.A.Forget, J.Chacon, C.Bernatchez, C.Haymaker, J.Q.Chen, P.Hwu, L.G.Radvanyi. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma:Current status and future outlook. Cancer J 2012; 18:160-75; PMID:22453018; http://dx.doi.org/10.1097/PPO.0b013e31824d4465
89. M.E.Dudley, J.C.Yang, R.Sherry, M.S.Hughes, R.Royal, U.Kammula, P.F.Robbins, J.Huang, D.E.Citrin, S.F.Leitman, et al. Adoptive cell therapy for patients with metastatic melanoma:Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
90. S.A.Rosenberg, N.P.Restifo, J.C.Yang, R.A.Morgan, M.E.Dudley. Adoptive cell transfer:A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308
91. A.Mackensen, N.Meidenbauer, S.Vogl, M.Laumer, J.Berger, R.Andreesen. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006; 24:5060-9; PMID:17075125
92. A.Khammari, J.Nguyen, M.Saint-Jean, A.Knol, M.Pandolfino, G.Quereux, A.Brocard, L.Peuvrel, S.Saiagh, V.Bataille. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother 2015; 64:805-15